The University of Manchester

Professor Juan Valle

This award has been made to assist with project management costs for a third year of the 2nd line clinical study, ABC-06.

“ABC-06 – 2nd line treatment trial for patients with locally advanced/metastatic biliary tract cancers previously treated with cisplatin/gemcitabine chemotherapy.
Randomised: Active Symptom Control with OxMdG chemo (Oxaliplatin, L-folinic acid & 5FU) – against – Active Symptom Control”.